GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT03856047

CompletedPhase 2Results posted

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

Investigation of Safety and Efficacy of NNC0174-0833 for Weight Management - a Dose Finding Trial.

Lead sponsor

Novo Nordisk A/S

Assets

CagriSema / cagrilintide / Liraglutide

Listed sites

Recruiting sites

—

Enrollment

706

actual

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoint

•Body weight, % change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03856047

Org study IDNN9838-4433

Secondary ID2018-001945-14European Medicines Agency (EudraCT)

Secondary IDU1111-1214-0429World Health Organization (WHO)

Timeline

Milestones

Study first posted2019-02-27actual

Study start2019-03-01actual

Primary completion2020-03-02actual

Study completion2021-03-25actual

Results first posted2023-07-18actual

Last update posted2024-07-05actual

Assets

Investigational agents

CagriSema / cagrilintide Liraglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•18 years or older at the time of signing the informed consent.

•Female subject of non-childbearing potential or Male subject who is surgically sterilised (vasectomy) or who is willing to use adequate contraceptive methods (as required by local regulation or practice) throughout the trial (until 'end of trial').

•BMI equal to 30.0 kg/m^2 or greater or BMI equal to 27.0 kg/m^2 or greater with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension or dyslipidaemia (to be assessed at the investigator's discretion).

Exclusion criteria

•HbA1c equal to 48 mmol/mol (6.5 percentage) or greater as measured by the central laboratory at screening.

•A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days prior to screening irrespective of medical records.

Endpoints (54)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers

Glycemic / diabetes

Weight & body composition

Safety / tolerability / PK

Other (unclassified)

Weight & body composition

10 endpoints

Primary/registry result

Change in Body Weight (%)

Time frame:From baseline (week 0) to week 26

Body weight, % change

percent change from baseline, improvement

Posted result

Group	Value (mean), Percentage point of body weight	95% CI
Cagrilintide 0.3 mg	-6.1	—
Cagrilintide 0.6 mg	-6.9	—
Cagrilintide 1.2 mg	-8.5	—
Cagrilintide 2.4 mg	-9.5	—
Cagrilintide 4.5 mg	-10.8	—
Liraglutide 3.0 mg	-8.5	—
Pooled Placebo	-3.0	—

Treatment difference (%-points)-2.9995% CI-4.58 – -1.40p0.0002ANCOVA

Treatment difference (%-points)-3.7895% CI-5.38 – -2.17p<.0001ANCOVA

Treatment difference (%-points)-6.0795% CI-7.77 – -4.36p<.0001ANCOVA

Treatment difference (%-points)-6.6895% CI-8.28 – -5.09p<.0001ANCOVA

Treatment difference (%-points)-7.7995% CI-9.42 – -6.16p<.0001ANCOVA

Treatment difference (%-points)-5.9895% CI-7.61 – -4.35p<.0001ANCOVA

Treatment difference (%-points)2.9995% CI1.38 – 4.60p0.0003ANCOVA

Treatment difference (%-points)2.2095% CI0.57 – 3.84p0.0082ANCOVA

Treatment difference (%-points)-0.0995% CI-1.82 – 1.64p0.9209ANCOVA

Treatment difference (%-points)-0.7095% CI-2.33 – 0.92p0.3960ANCOVA

Treatment difference (%-points)-1.8195% CI-3.46 – -0.16p0.0316ANCOVA

Primary/protocol endpoint

Change in Body Weight (%)

Time frame:From baseline (week 0) to week 26

Body weight, % change

percent change from baseline, improvement

Secondary/registry result

Percentage of Participants With Weight Loss of ≥ 5% of Baseline Body Weight at 26 Weeks

Time frame:Week 26

≥5% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), Percentage of participants	95% CI
Cagrilintide 0.3 mg	57.47	—
Cagrilintide 0.6 mg	61.98	—
Cagrilintide 1.2 mg	75.84	—
Cagrilintide 2.4 mg	74.12	—
Cagrilintide 4.5 mg	88.74	—
Liraglutide 3.0 mg	76.16	—
Pooled Placebo	30.90	—

Secondary/registry result

Percentage of Participants With Weight Loss of ≥ 10% of Baseline Body Weight at 26 Weeks

Time frame:Week 26

≥10% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), Percentage of participants	95% CI
Cagrilintide 0.3 mg	15.28	—
Cagrilintide 0.6 mg	24.06	—
Cagrilintide 1.2 mg	35.79	—
Cagrilintide 2.4 mg	43.97	—
Cagrilintide 4.5 mg	53.49	—
Liraglutide 3.0 mg	39.43	—
Pooled Placebo	10.44	—

Secondary/registry result

Change in Body Weight (Kg)

Time frame:From baseline (week 0) to week 26

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (mean), Kilograms (kg)	95% CI
Cagrilintide 0.3 mg	-6.6	—
Cagrilintide 0.6 mg	-7.1	—
Cagrilintide 1.2 mg	-9.0	—
Cagrilintide 2.4 mg	-10.1	—
Cagrilintide 4.5 mg	-11.8	—
Liraglutide 3.0 mg	-9.1	—
Pooled Placebo	-3.2	—

Secondary/registry result

Change in Waist Circumference

Time frame:From baseline (week 0) to week 26

Waist circumference, change

change from baseline, improvement

Posted result

Group	Value (mean), centimeters (cm)	95% CI
Cagrilintide 0.3 mg	-6.2	—
Cagrilintide 0.6 mg	-6.2	—
Cagrilintide 1.2 mg	-7.7	—
Cagrilintide 2.4 mg	-8.1	—
Cagrilintide 4.5 mg	-9.5	—
Liraglutide 3.0 mg	-7.4	—
Pooled Placebo	-3.4	—

Secondary/protocol endpoint

Percentage of Participants With Weight Loss of ≥ 5% of Baseline Body Weight at 26 Weeks

Time frame:Week 26

≥5% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants With Weight Loss of ≥ 10% of Baseline Body Weight at 26 Weeks

Time frame:Week 26

≥10% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Change in Body Weight (Kg)

Time frame:From baseline (week 0) to week 26

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Change in Waist Circumference

Time frame:From baseline (week 0) to week 26

Waist circumference, change

change from baseline, improvement

Glycemic / diabetes

14 endpoints

Secondary/registry result

Change in Glycosylated Haemoglobin (HbA1c) (%-Point)

Time frame:From baseline (week 0) to week 26

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (mean), Percentage point of HbA1c	95% CI
Cagrilintide 0.3 mg	0.0	—
Cagrilintide 0.6 mg	-0.1	—
Cagrilintide 1.2 mg	-0.1	—
Cagrilintide 2.4 mg	-0.1	—
Cagrilintide 4.5 mg	-0.1	—
Liraglutide 3.0 mg	-0.3	—
Pooled Placebo	-0.1	—

Secondary/registry result

Change in HbA1c (mmol/Mol)

Time frame:From baseline (week 0) to week 26

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (mean), mmol/mol	95% CI
Cagrilintide 0.3 mg	-0.5	—
Cagrilintide 0.6 mg	-0.6	—
Cagrilintide 1.2 mg	-0.8	—
Cagrilintide 2.4 mg	-1.0	—
Cagrilintide 4.5 mg	-1.2	—
Liraglutide 3.0 mg	-2.9	—
Pooled Placebo	-0.6	—

Secondary/registry result

Change in Fasting Plasma Glucose (FPG) (mmol/L)

Time frame:From baseline (week 0) to week 26

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Posted result

Group	Value (mean), mmol/L	95% CI
Cagrilintide 0.3 mg	0.0	—
Cagrilintide 0.6 mg	0.0	—
Cagrilintide 1.2 mg	-0.2	—
Cagrilintide 2.4 mg	0.0	—
Cagrilintide 4.5 mg	-0.2	—
Liraglutide 3.0 mg	-0.5	—
Pooled Placebo	0.0	—

Secondary/registry result

Change in FPG (mg/dL)

Time frame:From baseline (week 0) to week 26

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Posted result

Group	Value (mean), mg/dL	95% CI
Cagrilintide 0.3 mg	-0.7	—
Cagrilintide 0.6 mg	-0.6	—
Cagrilintide 1.2 mg	-3.2	—
Cagrilintide 2.4 mg	0.0	—
Cagrilintide 4.5 mg	-3.7	—
Liraglutide 3.0 mg	-9.5	—
Pooled Placebo	-0.5	—

Secondary/registry result

Change in Fasting Insulin

Time frame:From baseline (week 0) to week 26

change from baseline, improvement

Posted result

Group	Value (mean), Picomoles per liter (pmol/L)	95% CI
Cagrilintide 0.3 mgWeek 0	103.88	—
Week 26	93.07	—
Cagrilintide 0.6 mgWeek 0	97.43	—
Week 26	82.98	—
Cagrilintide 1.2 mgWeek 0	96.44	—
Week 26	79.39	—
Cagrilintide 2.4 mgWeek 0	90.05	—
Week 26	71.22	—
Cagrilintide 4.5 mgWeek 0	109.99	—
Week 26	78.67	—
Liraglutide 3.0 mgWeek 0	95.80	—
Week 26	79.00	—
Pooled PlaceboWeek 0	105.77	—
Week 26	86.55	—

Secondary/registry result

Percentage Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)

Time frame:From baseline (week 0) to week 26

HOMA-IR (insulin sensitivity)

percent change from baseline, improvement

Posted result

Group	Value (mean), Percentage change of HOMA-IR	95% CI
Cagrilintide 0.3 mg	-0.05	—
Cagrilintide 0.6 mg	-0.60	—
Cagrilintide 1.2 mg	-1.09	—
Cagrilintide 2.4 mg	-0.72	—
Cagrilintide 4.5 mg	-2.12	—
Liraglutide 3.0 mg	-0.91	—
Pooled Placebo	-0.71	—

Secondary/registry result

Change in Homeostatic Model Assessment of Beta-cell Function (HOMA-beta)

Time frame:From baseline (week 0) to week 26

change from baseline, improvement

Posted result

Group	Value (mean), Percentage of Beta Cell Function	95% CI
Cagrilintide 0.3 mg	-10.7	—
Cagrilintide 0.6 mg	-20.0	—
Cagrilintide 1.2 mg	-18.3	—
Cagrilintide 2.4 mg	-29.9	—
Cagrilintide 4.5 mg	-39.7	—
Liraglutide 3.0 mg	16.3	—
Pooled Placebo	-26.0	—

Secondary/protocol endpoint

Change in Glycosylated Haemoglobin (HbA1c) (%-Point)

Time frame:From baseline (week 0) to week 26

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in HbA1c (mmol/Mol)

Time frame:From baseline (week 0) to week 26

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in Fasting Plasma Glucose (FPG) (mmol/L)

Time frame:From baseline (week 0) to week 26

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Change in FPG (mg/dL)

Time frame:From baseline (week 0) to week 26

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint/low confidence

Change in Fasting Insulin

Time frame:From baseline (week 0) to week 26

change from baseline, improvement

Secondary/protocol endpoint

Percentage Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)

Time frame:From baseline (week 0) to week 26

HOMA-IR (insulin sensitivity)

percent change from baseline, improvement

Secondary/protocol endpoint

Change in Homeostatic Model Assessment of Beta-cell Function (HOMA-beta)

Time frame:From baseline (week 0) to week 26

change from baseline, improvement

Cardiometabolic biomarkers

22 endpoints

Secondary/registry result

Change in Total Cholesterol

Time frame:From baseline (week 0) to week 26

Total cholesterol, change

change from baseline, improvement

LOINC 2093-3

Posted result

Group	Value (mean), Milligrams per deciliter (mg/dL)	95% CI
Cagrilintide 0.3 mg	3.9	—
Cagrilintide 0.6 mg	-1.8	—
Cagrilintide 1.2 mg	-3.1	—
Cagrilintide 2.4 mg	-2.9	—
Cagrilintide 4.5 mg	-5.4	—
Liraglutide 3.0 mg	-9.4	—
Pooled Placebo	0.1	—

Secondary/registry result

Change in High Density Lipoprotein (HDL) Cholesterol

Time frame:From baseline (week 0) to week 26

HDL-C, change

change from baseline, improvement

LOINC 2085-9

Posted result

Group	Value (mean), mg/dL	95% CI
Cagrilintide 0.3 mg	1.5	—
Cagrilintide 0.6 mg	1.9	—
Cagrilintide 1.2 mg	1.1	—
Cagrilintide 2.4 mg	1.8	—
Cagrilintide 4.5 mg	2.6	—
Liraglutide 3.0 mg	0.8	—
Pooled Placebo	0.1	—

Secondary/registry result

Change in Low Density Lipoprotein (LDL) Cholesterol

Time frame:From baseline (week 0) to week 26

LDL-C, change

change from baseline, improvement

LOINC 13457-7

Posted result

Group	Value (mean), mg/dL	95% CI
Cagrilintide 0.3 mg	5.2	—
Cagrilintide 0.6 mg	-0.3	—
Cagrilintide 1.2 mg	-0.5	—
Cagrilintide 2.4 mg	-0.9	—
Cagrilintide 4.5 mg	-2.7	—
Liraglutide 3.0 mg	-5.4	—
Pooled Placebo	-1.0	—

Secondary/registry result

Change in Very Low Density Lipoprotein (VLDL) Cholesterol

Time frame:From baseline (week 0) to week 26

VLDL, change

change from baseline, improvement

Posted result

Group	Value (mean), mg/dL	95% CI
Cagrilintide 0.3 mg	-2.8	—
Cagrilintide 0.6 mg	-3.4	—
Cagrilintide 1.2 mg	-3.6	—
Cagrilintide 2.4 mg	-3.8	—
Cagrilintide 4.5 mg	-5.4	—
Liraglutide 3.0 mg	-4.9	—
Pooled Placebo	0.9	—

Secondary/registry result

Change in Triglycerides

Time frame:From baseline (week 0) to week 26

Triglycerides, change

change from baseline, improvement

LOINC 2571-8

Posted result

Group	Value (mean), mg/dL	95% CI
Cagrilintide 0.3 mg	-13.29	—
Cagrilintide 0.6 mg	-16.25	—
Cagrilintide 1.2 mg	-17.98	—
Cagrilintide 2.4 mg	-19.24	—
Cagrilintide 4.5 mg	-30.35	—
Liraglutide 3.0 mg	-25.42	—
Pooled Placebo	8.17	—

Secondary/registry result

Change in Diastolic Blood Pressure (DBP)

Time frame:From baseline (week 0) to week 26

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Posted result

Group	Value (mean), millimeter of mercury (mmHg)	95% CI
Cagrilintide 0.3 mg	-2.2	—
Cagrilintide 0.6 mg	0.8	—
Cagrilintide 1.2 mg	-1.3	—
Cagrilintide 2.4 mg	-1.2	—
Cagrilintide 4.5 mg	-1.8	—
Pooled Placebo	-2.6	—

Secondary/registry result

Change in Systolic Blood Pressure (SBP)

Time frame:From baseline (week 0) to week 26

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Posted result

Group	Value (mean), mmHg	95% CI
Cagrilintide 0.3 mg	-4.9	—
Cagrilintide 0.6 mg	-0.9	—
Cagrilintide 1.2 mg	-4.9	—
Cagrilintide 2.4 mg	-5.0	—
Cagrilintide 4.5 mg	-6.2	—
Pooled Placebo	-3.8	—

Secondary/registry result

Change in Pulse

Time frame:From baseline (week 0) to week 26

Heart rate, change

change from baseline, improvement

Posted result

Group	Value (mean), beats per minute	95% CI
Cagrilintide 0.3 mg	-2.1	—
Cagrilintide 0.6 mg	-0.6	—
Cagrilintide 1.2 mg	-1.2	—
Cagrilintide 2.4 mg	-2.0	—
Cagrilintide 4.5 mg	-4.5	—
Liraglutide 3.0 mg	1.6	—
Pooled Placebo	-0.1	—

Secondary/registry result

Change in High Sensitivity C-reactive Protein (hsCRP)

Time frame:From baseline (week 0) to week 26

hs-CRP, change

change from baseline, improvement

LOINC 30522-7

Posted result

Group	Value (mean), milligrams per liter (mg/L)	95% CI
Cagrilintide 0.3 mgWeek 0	4.5	—
Week 26	3.5	—
Cagrilintide 0.6 mgWeek 0	4.6	—
Week 26	3.4	—
Cagrilintide 1.2 mgWeek 0	4.5	—
Week 26	4.6	—
Cagrilintide 2.4 mgWeek 0	5.8	—
Week 26	4.0	—
Cagrilintide 4.5 mgWeek 0	5.4	—
Week 26	3.4	—
Liraglutide 3.0 mgWeek 0	4.7	—
Week 26	3.5	—
Pooled PlaceboWeek 0	4.6	—
Week 26	3.9	—

Secondary/registry result

Change in Renin Activity

Time frame:From baseline (week 0) to week 26

change from baseline, descriptive

Posted result

Group	Value (mean), nanograms per milliliter per hour	95% CI
Cagrilintide 0.3 mg	2	—
Cagrilintide 0.6 mg	0	—
Cagrilintide 1.2 mg	1	—
Cagrilintide 2.4 mg	1	—
Cagrilintide 4.5 mg	1	—
Liraglutide 3.0 mg	0	—
Pooled Placebo	0	—

Secondary/protocol endpoint

Change in Total Cholesterol

Time frame:From baseline (week 0) to week 26

Total cholesterol, change

change from baseline, improvement

LOINC 2093-3

Secondary/protocol endpoint

Change in High Density Lipoprotein (HDL) Cholesterol

Time frame:From baseline (week 0) to week 26

HDL-C, change

change from baseline, improvement

LOINC 2085-9

Secondary/protocol endpoint

Change in Low Density Lipoprotein (LDL) Cholesterol

Time frame:From baseline (week 0) to week 26

LDL-C, change

change from baseline, improvement

LOINC 13457-7

Secondary/protocol endpoint

Change in Very Low Density Lipoprotein (VLDL) Cholesterol

Time frame:From baseline (week 0) to week 26

VLDL, change

change from baseline, improvement

Secondary/protocol endpoint

Change in Triglycerides

Time frame:From baseline (week 0) to week 26

Triglycerides, change

change from baseline, improvement

LOINC 2571-8

Secondary/protocol endpoint

Change in Diastolic Blood Pressure (DBP)

Time frame:From baseline (week 0) to week 26

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Secondary/protocol endpoint

Change in Systolic Blood Pressure (SBP)

Time frame:From baseline (week 0) to week 26

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Change in Pulse

Time frame:From baseline (week 0) to week 26

Heart rate, change

change from baseline, improvement

Secondary/protocol endpoint

Change in High Sensitivity C-reactive Protein (hsCRP)

Time frame:From baseline (week 0) to week 26

hs-CRP, change

change from baseline, improvement

LOINC 30522-7

Secondary/protocol endpoint

Change in Plasminogen Activator Inhibitor-1 (PAI-1) Activity

Time frame:From baseline (week 0) to week 26

change from baseline, improvement

Secondary/protocol endpoint

Change in Renin Activity

Time frame:From baseline (week 0) to week 26

change from baseline, improvement

Secondary/protocol endpoint

Change in Aldosterone

Time frame:From baseline (week 0) to week 26

change from baseline, improvement

Safety / tolerability / PK

6 endpoints

Secondary/registry result

Number of Treatment-emergent Adverse Events (TEAEs)

Time frame:From week 0 to week 32

Treatment-emergent AEs (any)

event count, event

Posted result

Group	Value (number), Events	95% CI
Cagrilintide 0.3 mg	335	—
Cagrilintide 0.6 mg	291	—
Cagrilintide 1.2 mg	361	—
Cagrilintide 2.4 mg	449	—
Cagrilintide 4.5 mg	460	—
Liraglutide 3.0 mg	470	—
Pooled Placebo	276	—

Secondary/registry result

Number of Treatment-emergent Serious Adverse Events (TESAEs)

Time frame:From week 0 to week 32

Serious AEs (any)

event count, event

Posted result

Group	Value (number), Events	95% CI
Cagrilintide 0.3 mg	8	—
Cagrilintide 0.6 mg	3	—
Cagrilintide 1.2 mg	8	—
Cagrilintide 2.4 mg	6	—
Cagrilintide 4.5 mg	4	—
Liraglutide 3.0 mg	4	—
Pooled Placebo	4	—

Secondary/registry result

Number of Participants With Occurrence of Anti-drug Antibodies Towards Cagrilintide

Time frame:From week 0 to week 32

Immunogenicity (ADA)

threshold achievement, event

Posted result

Group	Value (count_of_participants), Participants	95% CI
Cagrilintide 0.3 mg	51	—
Cagrilintide 0.6 mg	54	—
Cagrilintide 1.2 mg	52	—
Cagrilintide 2.4 mg	75	—
Cagrilintide 4.5 mg	75	—

Secondary/protocol endpoint

Number of Treatment-emergent Adverse Events (TEAEs)

Time frame:From week 0 to week 32

Treatment-emergent AEs (any)

event count, event

Secondary/protocol endpoint

Number of Treatment-emergent Serious Adverse Events (TESAEs)

Time frame:From week 0 to week 32

Serious AEs (any)

event count, event

Secondary/protocol endpoint

Number of Participants With Occurrence of Anti-drug Antibodies Towards Cagrilintide

Time frame:From week 0 to week 32

Immunogenicity (ADA)

threshold achievement, event

Other (unclassified)

2 endpoints

Secondary/registry result/low confidence

Change in Plasminogen Activator Inhibitor-1 (PAI-1) Activity

Time frame:From baseline (week 0) to week 26

change from baseline, descriptive

Secondary/registry result/low confidence

Change in Aldosterone

Time frame:From baseline (week 0) to week 26

change from baseline, descriptive

Posted result

Group	Value (mean), nanograms per deciliter (ng/dL)	95% CI
Cagrilintide 0.3 mg	0.8	—
Cagrilintide 0.6 mg	0.8	—
Cagrilintide 1.2 mg	0.7	—
Cagrilintide 2.4 mg	2.2	—
Cagrilintide 4.5 mg	1.1	—
Liraglutide 3.0 mg	1.0	—
Pooled Placebo	0.5	—

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Lancet (London, England)2021 Dec 11PMID34798060doi:10.1016/S0140-6736(21)01751-7via CT.gov reference + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.